Jaleh Fallah, Jianjin Xu, Hee-Koung Joeng, Chana Weinstock, Brian L Heiss, William F Maguire, Xin Gao, Joyce Cheng, Elaine Chang, Sundeep Agrawal, Mallorie H Fiero, Richard Pazdur, Paul G Kluetz, Laleh Amiri-Kordestani, Daniel L Suzman
{"title":"循环肿瘤DNA假阳性结果不能解释PARP抑制剂对携带ATM和CHEK2突变的阉割耐药前列腺癌患者缺乏疗效。","authors":"Jaleh Fallah, Jianjin Xu, Hee-Koung Joeng, Chana Weinstock, Brian L Heiss, William F Maguire, Xin Gao, Joyce Cheng, Elaine Chang, Sundeep Agrawal, Mallorie H Fiero, Richard Pazdur, Paul G Kluetz, Laleh Amiri-Kordestani, Daniel L Suzman","doi":"10.1200/PO.24.00354","DOIUrl":null,"url":null,"abstract":"<p><p>False-positive ctDNA results do not explain lack of efficacy for PARPi in patients with ATMm and CHEK2m CRPC.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"8 ","pages":"e2400354"},"PeriodicalIF":5.3000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371381/pdf/","citationCount":"0","resultStr":"{\"title\":\"False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring <i>ATM</i> and <i>CHEK2</i> Mutations.\",\"authors\":\"Jaleh Fallah, Jianjin Xu, Hee-Koung Joeng, Chana Weinstock, Brian L Heiss, William F Maguire, Xin Gao, Joyce Cheng, Elaine Chang, Sundeep Agrawal, Mallorie H Fiero, Richard Pazdur, Paul G Kluetz, Laleh Amiri-Kordestani, Daniel L Suzman\",\"doi\":\"10.1200/PO.24.00354\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>False-positive ctDNA results do not explain lack of efficacy for PARPi in patients with ATMm and CHEK2m CRPC.</p>\",\"PeriodicalId\":14797,\"journal\":{\"name\":\"JCO precision oncology\",\"volume\":\"8 \",\"pages\":\"e2400354\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371381/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO precision oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1200/PO.24.00354\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO precision oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/PO.24.00354","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations.
False-positive ctDNA results do not explain lack of efficacy for PARPi in patients with ATMm and CHEK2m CRPC.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
